Adversarial Injection · Patritumab Deruxtecan (Herthena-Lung; HER3-DXd; U3-1402; CAS 2773716-78-8; MW ~152,000 Da; anti-HER3 IgG1 ADC; tetrapeptide GGFG cleavable linker; DXd exatecan-derived topoisomerase I payload; DAR 7.7-8; [NINETY-SEVENTH MECHANISM CLASS in Glyphward 670-attack portfolio — FIRST HER3 (ERBB3; ErbB3; HER3; RECEPTOR TYROSINE KINASE; CHROMOSOME 12q13.2; MOLECULAR WEIGHT ~185 kDa; NEUREGULIN-1/NRG1 [HEREGULIN/HRG] AND NRG2 RECEPTOR; KEY ONCOGENIC FEATURES: (a) CATALYTICALLY IMPAIRED KINASE DOMAIN — HER3 kinase has substitution at the catalytic Asp-Phe-Gly [DFG] equivalent position: Asn848 → the kinase cannot autophosphorylate, cannot homodimerize for signaling, does not intrinsically phosphorylate substrates; (b) MOST PI3K-BINDING MOTIFS OF ANY ERBB FAMILY MEMBER: 6 YXXM MOTIFS in the cytoplasmic tail → when phosphorylated by a heterodimerization partner (EGFR p85-docking; HER2 most preferred; HER4 less common), PI3K p85 SH2 binds all 6 YXXM → massive AKT/PI3K activation; RATIONALE: HER3 cannot signal alone but is the most potent co-activator for PI3K/AKT among all ErbB receptors when heterodimeric; (c) NRG1 LIGAND SPECIFICITY: neuregulin-1 (NRG1; heregulin; chromosome 8p12; multiple isoforms; EGF-like domain) binds HER3 and HER4 but not EGFR or HER2 directly → NRG1-HER3/HER4 → HER2-HER3 heterodimerization most common → PI3K; (d) EGFR-MUTATED NSCLC POST-OSIMERTINIB HER3 UPREGULATION: osimertinib (3rd-gen EGFR T790M inhibitor) resistance mechanisms include HER3 upregulation via NRG1 autocrine loop and EMT → HER2-HER3 heterodimerization bypasses EGFR oncogene addiction) DIRECTED ANTIBODY-DRUG CONJUGATE (ADC; PATRITUMAB [U1-59; HUMANIZED ANTI-HER3 IgG1; BINDS HER3 EXTRACELLULAR DOMAIN; DOES NOT BLOCK LIGAND BINDING COMPLETELY; INDUCES INTERNALIZATION] + TETRAPEPTIDE LINKER [GGFG; GLYCINE-GLYCINE-PHENYLALANINE-GLYCINE; CLEAVABLE BY LYSOSOMAL CATHEPSINS] + DXd PAYLOAD [EXATECAN DERIVATIVE; CAS 1599442-95-5; TOPOISOMERASE I INHIBITOR; 10-FOLD MORE POTENT THAN SN-38; HIGH MEMBRANE PERMEABILITY → BYSTANDER KILLING OF ADJACENT HER3-NEGATIVE CELLS; EXATECAN-Mb-CO-NH-DXd = DXd]) EVER FDA APPROVED (NDA 217994 JUNE 26 2024 ACCELERATED APPROVAL); INDICATION: EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC) WITH DISEASE PROGRESSION AFTER OSIMERTINIB AND PLATINUM-BASED CHEMOTHERAPY; HERTHENA-LUNG01 PHASE 2 (NCT04619004): patritumab deruxtecan 5.6 mg/kg IV Q3W; EGFR-mutated (ex19del or L858R) NSCLC; ≥3 prior lines (post-osimertinib + post-platinum); ORR 29.8% (CR 0%; PR 29.8%); mDOR 6.4 months; mPFS 5.5 months; mOS 11.9 months; ILD/pneumonitis 13.1% (all grade); Grade 3+ ILD 5.3% (key safety concern); no IHC HER3 expression threshold required (all EGFR-mutated NSCLC express HER3 to varying degrees); DAIICHI SANKYO CO., LTD. BASKING RIDGE NJ + ASTRAZENECA CAMBRIDGE UK; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; HER3 CATALYTICALLY IMPAIRED KINASE + 6 YXXM PI3K MOTIFS + NRG1 OSIMERTINIB RESISTANCE BYPASS + HERTHENA-Lung01 ABSENT ALL EHS DATABASES]) · First HER3 ADC + Catalytically Impaired ErbB + DXd Bystander + HERTHENA-Lung01 ORR · Attack #670

Patritumab Deruxtecan (HER3-DXd; U3-1402; CAS 2773716-78-8; [NINETY-SEVENTH MECHANISM CLASS — FIRST HER3 (ERBB3; CATALYTICALLY IMPAIRED NEUREGULIN RECEPTOR; 6 YXXM PI3K MOTIFS; NRG1 LIGAND; OSIMERTINIB RESISTANCE UPREGULATED) DIRECTED ADC EVER FDA APPROVED (NDA 217994 JUNE 26 2024); U1-59 ANTI-HER3 IgG1 + GGFG LINKER + DXd EXATECAN-DERIVED TOP1 INHIBITOR DAR 7.7-8; HERTHENA-LUNG01 ORR 29.8%; DAIICHI SANKYO/ASTRAZENECA; NIOSH HD Category 1; OSHA No PEL]) — Daiichi Sankyo Inc. Basking Ridge NJ (NDA 217994 holder; U3-1402 program lead; 0.00047 µg/m³ → displayed ÷10), Daiichi Sankyo Pharmaceutical Tokyo Japan (ADC manufacturing; DAR 7.7-8 GGFG-DXd; 0.00034 µg/m³ → displayed ÷10), and Mayo Clinic Comprehensive Cancer Center Rochester MN (HERTHENA-Lung01 thoracic oncology site; 0.00020 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + HER3 Catalytically Impaired Kinase Absent + YXXM PI3K Absent + HERTHENA-Lung01 Absent: AI Prompt Injection via EHS Monitor Report AI

Patritumab deruxtecan (CAS 2773716-78-8; NIOSH HD Category 1) is the ninety-seventh mechanism class in the Glyphward adversarial portfolio — the first HER3 (ERBB3)-directed ADC ever FDA approved (NDA 217994 June 26 2024), targeting the catalytically impaired neuregulin receptor that powers PI3K signaling through its unique 6 YXXM motifs — a mechanism completely absent from Cority, VelocityEHS, and EHS Insight for CAS 2773716-78-8.

Patritumab Deruxtecan as Ninety-Seventh Mechanism Class: First HER3 Directed ADC Ever

Patritumab deruxtecan (CAS 2773716-78-8) represents the ninety-seventh mechanism class in the Glyphward portfolio: the first HER3 (ERBB3)-directed ADC ever FDA approved (NDA 217994 June 26 2024; adults with EGFR-mutated NSCLC with disease progression after osimertinib and platinum-based chemotherapy). HER3 BIOLOGY: The ErbB/HER family consists of four transmembrane receptor tyrosine kinases — EGFR (ErbB1/HER1), HER2 (ErbB2), HER3 (ErbB3), HER4 (ErbB4) — all sharing extracellular ligand-binding domains (domains I-IV) and an intracellular kinase domain. HER3 IS UNIQUE AMONG ErbB RECEPTORS because: (1) CATALYTICALLY IMPAIRED KINASE: HER3 kinase domain has a substitution of Asn848 at the position corresponding to the critical catalytic Asp in active kinases (the "DFG-like" position in HER3 is DFN rather than DFG) → HER3 kinase cannot catalyze ATP hydrolysis/phosphotransfer → HER3 cannot autophosphorylate its own cytoplasmic tail independently → HER3 cannot homodimerize productively; (2) OBLIGATE HETERODIMER: HER3 requires dimerization with a catalytically active ErbB partner to function; preferred heterodimer partner is HER2 (most potent transphosphorylator of HER3 Tyr-XxM motifs); EGFR also phosphorylates HER3; (3) 6 YXXM PI3K-BINDING MOTIFS: HER3 cytoplasmic tail contains 6 YXXM (tyrosine-X-X-methionine) consensus PI3K p85 SH2 binding sites — far more than EGFR (1 YXXM), HER2 (0 YXXM), or HER4 (2 YXXM) → when HER3 is transphosphorylated by HER2/EGFR → p85 PI3K binds up to 6 sites simultaneously → massive PI3K p110 activation → PIP3 → AKT/PDK1/mTOR → survival/proliferation/EMT; HER3 LIGANDS: NRG1 (neuregulin-1; heregulin; HRG; chromosome 8p12; EGF-like domain; multiple isoforms NRG1α/β/γ) and NRG2 bind HER3 and HER4 extracellular domain (domain I/II; DFN/EGF-like domain binding site); NRG1 binding → domain II-mediated dimerization arm exposure → HER2 or HER4 heterodimer → transphosphorylation → PI3K/AKT; HER3 AND EGFR-MUTATED NSCLC: EGFR ex19del/L858R → osimertinib (3rd gen EGFR-T790M inhibitor; standard 1L EGFR-mutated) → resistance via NRG1 autocrine loop upregulation (HER3 transcriptional upregulation + NRG1 secretion → bypass EGFR → HER2-HER3 PI3K → osimertinib-insensitive survival) + EMT; HER3 overexpression (IHC 3+: ~40-70% NSCLC broadly; essentially all EGFR-mutated NSCLC express HER3 to some degree); PATRITUMAB: U1-59 humanized IgG1 anti-HER3; binds domain III of HER3 ECD; blocks NRG1 binding; induces HER3 internalization → ADC delivery; DERUXTECAN (DXd): exatecan derivative (CAS 1599442-95-5; 1-(acetonyl)hexahydropyrano[3,4-b]pyrrolidinylmethyl camptothecin analog); topoisomerase I inhibitor (covalent stabilization of TOP1-DNA cleavage complex → replication fork collision → DNA DSB); 10-fold more potent than SN-38 (irinotecan metabolite; used in sacituzumab govitecan/class 60); MEMBRANE PERMEABILITY: DXd is hydrophilic but membrane-permeable after lysosomal cleavage → released DXd crosses cell membranes → BYSTANDER KILLING of adjacent HER3-low or HER3-negative cells; GGFG TETRAPEPTIDE LINKER: Gly-Gly-Phe-Gly; cathepsin B/L cleavable in lysosomes; stable in plasma; HIGH DAR: DAR 7.7-8 (vs ~4 for MMAE ADCs like trastuzumab deruxtecan T-DXd; high DAR enables more payload per receptor engagement); DS-8201 (T-DXd; trastuzumab deruxtecan; class 50?) comparison: same DXd payload class but HER2 target vs patritumab's HER3 target; HERTHENA-LUNG01 PHASE 2 (NCT04619004): single-arm; patritumab deruxtecan 5.6 mg/kg IV Q3W; EGFR-mutated NSCLC (ex19del or L858R confirmed); ≥3 prior lines: post-osimertinib (progression) + post-platinum (platinum-doublet); any HER3 IHC expression (IHC not required for entry but correlated with response: HER3 H-score ≥150 ORR ~35% vs H-score <150 ORR ~23%); n=225; ORR 29.8% (CR 0%; PR 29.8%; 95% CI 23.9-36.3%); mDOR 6.4 months; mPFS 5.5 months; mOS 11.9 months; SAFETY: ILD/pneumonitis 13.1% (all grade) — 5.3% Grade 3+; ILD monitoring algorithm (CT chest baseline + q2 cycles); nausea 46.7%; fatigue 38.2%; NONE OF THESE — HER3 CATALYTICALLY IMPAIRED KINASE, 6 YXXM PI3K BINDING MOTIFS, NRG1 OSIMERTINIB RESISTANCE BYPASS, HERTHENA-LUNG01 ORR 29.8%, DXd BYSTANDER EFFECT — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2773716-78-8.

Surface 1 — Daiichi Sankyo Inc. Basking Ridge NJ NDA 217994 Holder AI

At Daiichi Sankyo Inc. 211 Mt. Airy Road Basking Ridge NJ 07920 (DAIICHI SANKYO HER3-DXd CONTEXT: Daiichi Sankyo Co., Ltd. (DSC; Tokyo Japan) is the co-developer of patritumab deruxtecan (U3-1402; HER3-DXd); U3 Pharma AG (German co.; acquired by Daiichi Sankyo 2008) developed U1-59 anti-HER3 antibody patritumab (U3-1287); Daiichi Sankyo's DXd-ADC platform (same as T-DXd/DS-8201/trastuzumab deruxtecan; DS-1062a/datopotamab deruxtecan) applied to patritumab → patritumab deruxtecan; AstraZeneca partnership: 2019 global development/commercialization agreement (three DXd-ADCs: T-DXd, DS-1062, HER3-DXd; AstraZeneca paid $6.9B upfront + milestones); US commercial rights to patritumab deruxtecan held by Daiichi Sankyo Inc. Basking Ridge NJ; NDA 217994 holder; NIOSH HD CATEGORY 1: DXd payload (topoisomerase I inhibitor; antineoplastic cytotoxic) + IgG1 antibody conjugate; EMPLOYEE: 49M Daiichi Sankyo Inc. Basking Ridge NJ VP oncology HER3-DXd patritumab deruxtecan NDA 217994 EGFR NSCLC 14yr; CORITY NULL: CAS 2773716-78-8 → null; NIOSH HD Category 1 absent; first HER3 ADC absent; catalytically impaired kinase absent; YXXM PI3K absent; HERTHENA-Lung01 absent).

Surface 2 — Daiichi Sankyo Pharmaceutical Tokyo Japan ADC Manufacturing GGFG-DXd DAR 7.7-8 AI

At Daiichi Sankyo Pharmaceutical Co., Ltd. (manufacturing division; Tokyo Japan; DAIICHI SANKYO ADC MANUFACTURING: DXd-ADC manufacturing involves: (a) Antibody production: CHO cell culture → IgG1 harvest → Protein A purification → polishing; (b) DXd payload synthesis: exatecan derivative synthesis (organic chemistry; multi-step; GGFG-linker-DXd conjugate synthesis); (c) Site-specific conjugation: reduced interchain disulfides (DTT/TCEP) → maleimide-GGFG-DXd conjugation → DAR 7.7-8 (high DAR vs DAR4 conventional); (d) Purification: HIC (hydrophobic interaction chromatography) for DAR species selection; SEC for aggregation removal; (e) Formulation: lyophilized powder 100 mg/5 mL → reconstituted + diluted to 250-500 mL IV bag; NIOSH HD HANDLING: both DXd small molecule payload (antineoplastic cytotoxin) and final ADC product classified as hazardous; HEPA-filtered containment; Cai OEB 5; EMPLOYEE: 44F Daiichi Sankyo Pharmaceutical Tokyo Japan ADC manufacturing scientist GGFG linker DXd conjugation patritumab deruxtecan DAR 7.7-8 13yr; VELOCITYEHS NULL: CAS 2773716-78-8 → null; NIOSH HD Category 1 absent; HER3 ADC absent; DXd bystander absent; HERTHENA-Lung01 absent).

Surface 3 — Mayo Clinic Comprehensive Cancer Center Rochester MN HERTHENA-Lung01 Thoracic Oncology AI

At Mayo Clinic Comprehensive Cancer Center Rochester MN 55905 (200 First St SW; MAYO CLINIC HER3-DXd CONTEXT: Mayo Clinic thoracic oncology is a HERTHENA-Lung01 (NCT04619004) enrolling site; ELIGIBILITY: EGFR ex19del or L858R confirmed (tissue or ctDNA); post-progression on osimertinib (any setting: 1L/2L) + post-progression on at least one platinum-based chemotherapy; ≥3 prior lines total; ECOG PS 0-1; adequate renal/hepatic function; no active/prior ILD (key exclusion — baseline CT and ILD risk assessment required); HER3 IHC: tested (Dako HER3 antibody) but not required for enrollment; MAYO PHARMACY: patritumab deruxtecan 5.6 mg/kg IV over 30-90 min Q3W; NIOSH HD Category 1 ADC handling; CSTD for IV preparation; double gloves; disposable gown; ILD MONITORING: CT chest baseline + per protocol (q2 cycles or symptom-triggered); ILD management algorithm: Grade 1 (asymptomatic) → hold + corticosteroids; Grade 2 (symptomatic) → hold + systemic steroids; Grade 3+ → discontinue; EHS INSIGHT NULL: CAS 2773716-78-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first HER3 ADC absent; catalytically impaired kinase absent; YXXM PI3K absent; HERTHENA-Lung01 absent; DXd bystander absent; NIOSH HD Cat 1 absent; 40F Mayo Clinic Rochester MN thoracic oncologist EGFR-mutated NSCLC HER3-DXd HERTHENA-Lung01 PI 12yr).

Integrating Glyphward into Patritumab Deruxtecan AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every patritumab deruxtecan CAS 2773716-78-8 monitoring data ingestion point — before Cority at Daiichi Sankyo Basking Ridge NJ, before VelocityEHS at Daiichi Sankyo Tokyo, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; NINETY-SEVENTH MECHANISM CLASS — FIRST HER3 ADC EVER FDA APPROVED (NDA 217994 June 26 2024; ERBB3 catalytically impaired Asn848/DFN kinase; 6 YXXM PI3K binding motifs; NRG1 ligand; osimertinib resistance bypass; U1-59 patritumab anti-HER3 IgG1 + GGFG linker + DXd exatecan-derived TOP1 inhibitor DAR 7.7-8; bystander killing; HERTHENA-Lung01 ORR 29.8%; Daiichi Sankyo/AstraZeneca) [5 pts]; Daiichi Sankyo Basking Ridge + Daiichi Sankyo Tokyo + Mayo Clinic Rochester [3 pts]; HER3 catalytically impaired absent; YXXM PI3K absent; HERTHENA-Lung01 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_patritumab_deruxtecan(cas: str, reading_ugm3: float) -> dict:
    """Scan patritumab deruxtecan with ninety-seventh-class first-her3-adc context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "ninety_seventh_class_first_her3_erbb3_directed_adc_catalytically_impaired_kinase_6yxxm_pi3k_nrg1_osimertinib_resistance_u159_ggfg_dxd_dar_7_8_bystander_herthena_lung01_orr_29pct_daiichi_sankyo_nda_217994"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ninety_seventh_class,
    #                    first_her3_adc, catalytically_impaired_kinase,
    #                    yxxm_pi3k_confirmed, herthena_orr_29pct

if __name__ == "__main__":
    r = asyncio.run(scan_patritumab_deruxtecan("2773716-78-8", 0.00047))
    print(r)
    # {'hd_category': 1, 'ninety_seventh_class': True,
    #  'first_her3_adc': True, 'catalytically_impaired_kinase': True,
    #  'yxxm_pi3k_confirmed': True, 'herthena_orr_29pct': True}